Adaptive Biotechnologies (ADPT) is back in focus after announcing that its clonoSEQ minimal residual disease test will be featured in 33 presentations at the ASCO Annual Meeting and the upcoming EHA Congress, including one plenary session.

Recent conference appearances and the ASCO and EHA data spotlight come as the stock trades at US$15.23, with a 7 day share price return of 9.73% but a year to date share price return that is down 4.27%. Over a longer horizon, total shareholder return has been mixed, with a 1 year total shareholder return of 59.48% and a 5 year total shareholder return that is down 59.67%, suggesting recent momentum follows a much weaker earlier period.

If this kind of healthcare focused data story interests you, it may be worth broadening your watchlist with other specialized opportunities using our healthcare AI stocks screener, starting with 40 healthcare AI stocks.

With the clonoSEQ test in the spotlight and the stock trading below some valuation estimates, the key question for you is simple: Is Adaptive Biotechnologies still undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 30.8% Undervalued

At a last close of $15.23 against a widely followed fair value of $22, the current share price sits well below the narrative's valuation anchor. This puts the focus squarely on what has to go right in the business for that gap to close.

Expansion of indications into non-hematologic diseases and earlier-stage pipeline assets, alongside a growing international pharma trial backlog and industry momentum behind using MRD as a primary endpoint, create material upside to top-line growth and diversify Adaptive's revenue base well beyond what current forecasts and multiples imply.

Want to see what underpins that confidence in future cash flows? The narrative leans on stronger revenue momentum, improving margins, and a punchy earnings multiple. Curious which assumptions really move the fair value dial?

Result: Fair Value of $22 (UNDERVALUED)

However, there are still clear pressure points, including ongoing losses at the group level and reliance on key partnerships that, if disrupted, could quickly challenge this upbeat setup.

Another Angle: Price To Sales Sends A Different Signal

While the narrative and fair value work point to upside, the simple P/S yardstick looks far less forgiving. At 8.3x sales, Adaptive Biotechnologies trades well above the US Life Sciences industry at 3.9x, peers at 6.6x, and even the 4x fair ratio that the market could move toward. If sentiment cools, how comfortable are you holding a stock that already carries this kind of premium?

Next Steps

See enough to form a first impression, but still unsure where you stand on the stock? Act quickly, review the data from both sides, and then weigh the 4 key rewards and 2 important warning signs.

Looking for more investment ideas?

If you only stop at one stock, you risk missing out on other opportunities that might fit your style even better, so broaden your search with a few targeted screens.

• Target potential bargains trading below estimated value and sharpen your watchlist by starting with 47 high quality undervalued stocks.
• Zero in on companies that prioritize returning cash to shareholders by checking out 10 dividend fortresses.
• Prioritize resilience and sleep easier at night by filtering for 62 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.